 | • レポートコード：MRC2-11QY12258 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はヒト血漿由来治療薬のグローバル市場について調査・分析したレポートです。種類別（アルブミン、免疫グロブリン、凝固因子、プロトロンビン複合体濃縮物、その他）市場規模、用途別（病院、診療所、研究センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別ヒト血漿由来治療薬の競争状況、市場シェア ・世界のヒト血漿由来治療薬市場：種類別市場規模 2015年-2020年（アルブミン、免疫グロブリン、凝固因子、プロトロンビン複合体濃縮物、その他） ・世界のヒト血漿由来治療薬市場：種類別市場規模予測 2021年-2026年（アルブミン、免疫グロブリン、凝固因子、プロトロンビン複合体濃縮物、その他） ・世界のヒト血漿由来治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、研究センター） ・世界のヒト血漿由来治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、研究センター） ・北米のヒト血漿由来治療薬市場分析：米国、カナダ ・ヨーロッパのヒト血漿由来治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのヒト血漿由来治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のヒト血漿由来治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのヒト血漿由来治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Alkahest、Baxter、CSL Behring、Entegrion, Inc.、Gammagard、Grifols、Kedrion、Octapharma、Prometic Life Sciences、Sanquin、Takeda ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Human Plasma-Derived Therapeutics Market
The global Human Plasma-Derived Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Human Plasma-Derived Therapeutics Scope and Market Size
Human Plasma-Derived Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Human Plasma-Derived Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Alkahest
Baxter
CSL Behring
Entegrion, Inc.
Gammagard
Grifols
Kedrion
Octapharma
Prometic Life Sciences
Sanquin
Takeda
Market segment by Type, the product can be split into
Albumin
Immunoglobulin
Clotting Factor
Prothrombin Complex
Others
Market segment by Application, split into
Hospital
Clinic
Research Center
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Human Plasma-Derived Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Human Plasma-Derived Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Albumin
1.4.3 Immunoglobulin
1.4.4 Clotting Factor
1.4.5 Prothrombin Complex
1.4.6 Others
1.5 Market by Application
1.5.1 Global Human Plasma-Derived Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Research Center
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Human Plasma-Derived Therapeutics Market Perspective (2015-2026)
2.2 Global Human Plasma-Derived Therapeutics Growth Trends by Regions
2.2.1 Human Plasma-Derived Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Human Plasma-Derived Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Human Plasma-Derived Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Human Plasma-Derived Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Human Plasma-Derived Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Human Plasma-Derived Therapeutics Players by Market Size
3.1.1 Global Top Human Plasma-Derived Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Human Plasma-Derived Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Human Plasma-Derived Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Human Plasma-Derived Therapeutics Market Concentration Ratio
3.2.1 Global Human Plasma-Derived Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Human Plasma-Derived Therapeutics Revenue in 2019
3.3 Human Plasma-Derived Therapeutics Key Players Head office and Area Served
3.4 Key Players Human Plasma-Derived Therapeutics Product Solution and Service
3.5 Date of Enter into Human Plasma-Derived Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Human Plasma-Derived Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Human Plasma-Derived Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Human Plasma-Derived Therapeutics Market Size by Application (2015-2020)
5.2 Global Human Plasma-Derived Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Human Plasma-Derived Therapeutics Market Size (2015-2020)
6.2 Human Plasma-Derived Therapeutics Key Players in North America (2019-2020)
6.3 North America Human Plasma-Derived Therapeutics Market Size by Type (2015-2020)
6.4 North America Human Plasma-Derived Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Human Plasma-Derived Therapeutics Market Size (2015-2020)
7.2 Human Plasma-Derived Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Human Plasma-Derived Therapeutics Market Size by Type (2015-2020)
7.4 Europe Human Plasma-Derived Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Human Plasma-Derived Therapeutics Market Size (2015-2020)
8.2 Human Plasma-Derived Therapeutics Key Players in China (2019-2020)
8.3 China Human Plasma-Derived Therapeutics Market Size by Type (2015-2020)
8.4 China Human Plasma-Derived Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Human Plasma-Derived Therapeutics Market Size (2015-2020)
9.2 Human Plasma-Derived Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Human Plasma-Derived Therapeutics Market Size by Type (2015-2020)
9.4 Japan Human Plasma-Derived Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Human Plasma-Derived Therapeutics Market Size (2015-2020)
10.2 Human Plasma-Derived Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Human Plasma-Derived Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Human Plasma-Derived Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Human Plasma-Derived Therapeutics Market Size (2015-2020)
11.2 Human Plasma-Derived Therapeutics Key Players in India (2019-2020)
11.3 India Human Plasma-Derived Therapeutics Market Size by Type (2015-2020)
11.4 India Human Plasma-Derived Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Human Plasma-Derived Therapeutics Market Size (2015-2020)
12.2 Human Plasma-Derived Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Human Plasma-Derived Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Human Plasma-Derived Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Alkahest
13.1.1 Alkahest Company Details
13.1.2 Alkahest Business Overview
13.1.3 Alkahest Human Plasma-Derived Therapeutics Introduction
13.1.4 Alkahest Revenue in Human Plasma-Derived Therapeutics Business (2015-2020))
13.1.5 Alkahest Recent Development
13.2 Baxter
13.2.1 Baxter Company Details
13.2.2 Baxter Business Overview
13.2.3 Baxter Human Plasma-Derived Therapeutics Introduction
13.2.4 Baxter Revenue in Human Plasma-Derived Therapeutics Business (2015-2020)
13.2.5 Baxter Recent Development
13.3 CSL Behring
13.3.1 CSL Behring Company Details
13.3.2 CSL Behring Business Overview
13.3.3 CSL Behring Human Plasma-Derived Therapeutics Introduction
13.3.4 CSL Behring Revenue in Human Plasma-Derived Therapeutics Business (2015-2020)
13.3.5 CSL Behring Recent Development
13.4 Entegrion, Inc.
13.4.1 Entegrion, Inc. Company Details
13.4.2 Entegrion, Inc. Business Overview
13.4.3 Entegrion, Inc. Human Plasma-Derived Therapeutics Introduction
13.4.4 Entegrion, Inc. Revenue in Human Plasma-Derived Therapeutics Business (2015-2020)
13.4.5 Entegrion, Inc. Recent Development
13.5 Gammagard
13.5.1 Gammagard Company Details
13.5.2 Gammagard Business Overview
13.5.3 Gammagard Human Plasma-Derived Therapeutics Introduction
13.5.4 Gammagard Revenue in Human Plasma-Derived Therapeutics Business (2015-2020)
13.5.5 Gammagard Recent Development
13.6 Grifols
13.6.1 Grifols Company Details
13.6.2 Grifols Business Overview
13.6.3 Grifols Human Plasma-Derived Therapeutics Introduction
13.6.4 Grifols Revenue in Human Plasma-Derived Therapeutics Business (2015-2020)
13.6.5 Grifols Recent Development
13.7 Kedrion
13.7.1 Kedrion Company Details
13.7.2 Kedrion Business Overview
13.7.3 Kedrion Human Plasma-Derived Therapeutics Introduction
13.7.4 Kedrion Revenue in Human Plasma-Derived Therapeutics Business (2015-2020)
13.7.5 Kedrion Recent Development
13.8 Octapharma
13.8.1 Octapharma Company Details
13.8.2 Octapharma Business Overview
13.8.3 Octapharma Human Plasma-Derived Therapeutics Introduction
13.8.4 Octapharma Revenue in Human Plasma-Derived Therapeutics Business (2015-2020)
13.8.5 Octapharma Recent Development
13.9 Prometic Life Sciences
13.9.1 Prometic Life Sciences Company Details
13.9.2 Prometic Life Sciences Business Overview
13.9.3 Prometic Life Sciences Human Plasma-Derived Therapeutics Introduction
13.9.4 Prometic Life Sciences Revenue in Human Plasma-Derived Therapeutics Business (2015-2020)
13.9.5 Prometic Life Sciences Recent Development
13.10 Sanquin
13.10.1 Sanquin Company Details
13.10.2 Sanquin Business Overview
13.10.3 Sanquin Human Plasma-Derived Therapeutics Introduction
13.10.4 Sanquin Revenue in Human Plasma-Derived Therapeutics Business (2015-2020)
13.10.5 Sanquin Recent Development
13.11 Takeda
10.11.1 Takeda Company Details
10.11.2 Takeda Business Overview
10.11.3 Takeda Human Plasma-Derived Therapeutics Introduction
10.11.4 Takeda Revenue in Human Plasma-Derived Therapeutics Business (2015-2020)
10.11.5 Takeda Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Human Plasma-Derived Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Human Plasma-Derived Therapeutics Revenue
Table 3. Ranking of Global Top Human Plasma-Derived Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Human Plasma-Derived Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Albumin
Table 6. Key Players of Immunoglobulin
Table 7. Key Players of Clotting Factor
Table 8. Key Players of Prothrombin Complex
Table 9. Key Players of Others
Table 10. Global Human Plasma-Derived Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Human Plasma-Derived Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Human Plasma-Derived Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Human Plasma-Derived Therapeutics Market Share by Regions (2015-2020)
Table 14. Global Human Plasma-Derived Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Human Plasma-Derived Therapeutics Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Human Plasma-Derived Therapeutics Market Growth Strategy
Table 20. Main Points Interviewed from Key Human Plasma-Derived Therapeutics Players
Table 21. Global Human Plasma-Derived Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 22. Global Human Plasma-Derived Therapeutics Market Share by Players (2015-2020)
Table 23. Global Top Human Plasma-Derived Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Plasma-Derived Therapeutics as of 2019)
Table 24. Global Human Plasma-Derived Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Human Plasma-Derived Therapeutics Product Solution and Service
Table 27. Date of Enter into Human Plasma-Derived Therapeutics Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Human Plasma-Derived Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 30. Global Human Plasma-Derived Therapeutics Market Size Share by Type (2015-2020)
Table 31. Global Human Plasma-Derived Therapeutics Revenue Market Share by Type (2021-2026)
Table 32. Global Human Plasma-Derived Therapeutics Market Size Share by Application (2015-2020)
Table 33. Global Human Plasma-Derived Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 34. Global Human Plasma-Derived Therapeutics Market Size Share by Application (2021-2026)
Table 35. North America Key Players Human Plasma-Derived Therapeutics Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Human Plasma-Derived Therapeutics Market Share (2019-2020)
Table 37. North America Human Plasma-Derived Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 38. North America Human Plasma-Derived Therapeutics Market Share by Type (2015-2020)
Table 39. North America Human Plasma-Derived Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 40. North America Human Plasma-Derived Therapeutics Market Share by Application (2015-2020)
Table 41. Europe Key Players Human Plasma-Derived Therapeutics Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Human Plasma-Derived Therapeutics Market Share (2019-2020)
Table 43. Europe Human Plasma-Derived Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Human Plasma-Derived Therapeutics Market Share by Type (2015-2020)
Table 45. Europe Human Plasma-Derived Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Human Plasma-Derived Therapeutics Market Share by Application (2015-2020)
Table 47. China Key Players Human Plasma-Derived Therapeutics Revenue (2019-2020) (Million US$)
Table 48. China Key Players Human Plasma-Derived Therapeutics Market Share (2019-2020)
Table 49. China Human Plasma-Derived Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 50. China Human Plasma-Derived Therapeutics Market Share by Type (2015-2020)
Table 51. China Human Plasma-Derived Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 52. China Human Plasma-Derived Therapeutics Market Share by Application (2015-2020)
Table 53. Japan Key Players Human Plasma-Derived Therapeutics Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Human Plasma-Derived Therapeutics Market Share (2019-2020)
Table 55. Japan Human Plasma-Derived Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Human Plasma-Derived Therapeutics Market Share by Type (2015-2020)
Table 57. Japan Human Plasma-Derived Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Human Plasma-Derived Therapeutics Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Human Plasma-Derived Therapeutics Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Human Plasma-Derived Therapeutics Market Share (2019-2020)
Table 61. Southeast Asia Human Plasma-Derived Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Human Plasma-Derived Therapeutics Market Share by Type (2015-2020)
Table 63. Southeast Asia Human Plasma-Derived Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Human Plasma-Derived Therapeutics Market Share by Application (2015-2020)
Table 65. India Key Players Human Plasma-Derived Therapeutics Revenue (2019-2020) (Million US$)
Table 66. India Key Players Human Plasma-Derived Therapeutics Market Share (2019-2020)
Table 67. India Human Plasma-Derived Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 68. India Human Plasma-Derived Therapeutics Market Share by Type (2015-2020)
Table 69. India Human Plasma-Derived Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 70. India Human Plasma-Derived Therapeutics Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Human Plasma-Derived Therapeutics Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Human Plasma-Derived Therapeutics Market Share (2019-2020)
Table 73. Central & South America Human Plasma-Derived Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Human Plasma-Derived Therapeutics Market Share by Type (2015-2020)
Table 75. Central & South America Human Plasma-Derived Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Human Plasma-Derived Therapeutics Market Share by Application (2015-2020)
Table 77. Alkahest Company Details
Table 78. Alkahest Business Overview
Table 79. Alkahest Product
Table 80. Alkahest Revenue in Human Plasma-Derived Therapeutics Business (2015-2020) (Million US$)
Table 81. Alkahest Recent Development
Table 82. Baxter Company Details
Table 83. Baxter Business Overview
Table 84. Baxter Product
Table 85. Baxter Revenue in Human Plasma-Derived Therapeutics Business (2015-2020) (Million US$)
Table 86. Baxter Recent Development
Table 87. CSL Behring Company Details
Table 88. CSL Behring Business Overview
Table 89. CSL Behring Product
Table 90. CSL Behring Revenue in Human Plasma-Derived Therapeutics Business (2015-2020) (Million US$)
Table 91. CSL Behring Recent Development
Table 92. Entegrion, Inc. Company Details
Table 93. Entegrion, Inc. Business Overview
Table 94. Entegrion, Inc. Product
Table 95. Entegrion, Inc. Revenue in Human Plasma-Derived Therapeutics Business (2015-2020) (Million US$)
Table 96. Entegrion, Inc. Recent Development
Table 97. Gammagard Company Details
Table 98. Gammagard Business Overview
Table 99. Gammagard Product
Table 100. Gammagard Revenue in Human Plasma-Derived Therapeutics Business (2015-2020) (Million US$)
Table 101. Gammagard Recent Development
Table 102. Grifols Company Details
Table 103. Grifols Business Overview
Table 104. Grifols Product
Table 105. Grifols Revenue in Human Plasma-Derived Therapeutics Business (2015-2020) (Million US$)
Table 106. Grifols Recent Development
Table 107. Kedrion Company Details
Table 108. Kedrion Business Overview
Table 109. Kedrion Product
Table 110. Kedrion Revenue in Human Plasma-Derived Therapeutics Business (2015-2020) (Million US$)
Table 111. Kedrion Recent Development
Table 112. Octapharma Business Overview
Table 113. Octapharma Product
Table 114. Octapharma Company Details
Table 115. Octapharma Revenue in Human Plasma-Derived Therapeutics Business (2015-2020) (Million US$)
Table 116. Octapharma Recent Development
Table 117. Prometic Life Sciences Company Details
Table 118. Prometic Life Sciences Business Overview
Table 119. Prometic Life Sciences Product
Table 120. Prometic Life Sciences Revenue in Human Plasma-Derived Therapeutics Business (2015-2020) (Million US$)
Table 121. Prometic Life Sciences Recent Development
Table 122. Sanquin Company Details
Table 123. Sanquin Business Overview
Table 124. Sanquin Product
Table 125. Sanquin Revenue in Human Plasma-Derived Therapeutics Business (2015-2020) (Million US$)
Table 126. Sanquin Recent Development
Table 127. Takeda Company Details
Table 128. Takeda Business Overview
Table 129. Takeda Product
Table 130. Takeda Revenue in Human Plasma-Derived Therapeutics Business (2015-2020) (Million US$)
Table 131. Takeda Recent Development
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Human Plasma-Derived Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Albumin Features
Figure 3. Immunoglobulin Features
Figure 4. Clotting Factor Features
Figure 5. Prothrombin Complex Features
Figure 6. Others Features
Figure 7. Global Human Plasma-Derived Therapeutics Market Share by Application: 2020 VS 2026
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Research Center Case Studies
Figure 11. Human Plasma-Derived Therapeutics Report Years Considered
Figure 12. Global Human Plasma-Derived Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Human Plasma-Derived Therapeutics Market Share by Regions: 2020 VS 2026
Figure 14. Global Human Plasma-Derived Therapeutics Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Human Plasma-Derived Therapeutics Market Share by Players in 2019
Figure 17. Global Top Human Plasma-Derived Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Plasma-Derived Therapeutics as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Human Plasma-Derived Therapeutics Revenue in 2019
Figure 19. North America Human Plasma-Derived Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Human Plasma-Derived Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Human Plasma-Derived Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Human Plasma-Derived Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Human Plasma-Derived Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Human Plasma-Derived Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Human Plasma-Derived Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed
プラズマ治療薬の世界市場（～2026年） Plasma, pale yellow in color, is the component of the blood. To calculate the market size, the report considers revenue generated from the sales of branded therapies derived from the various fractions of plasma such as albumin, immunoglobulins, coagulation factors, hyperimmune globulins, and A1PI. M…- 間質細胞由来因子1の世界市場（～2026年） Market Analysis and Insights: Global Stromal Cell Derived Factor 1 Market The global Stromal Cell Derived Factor 1 market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Stromal Cell Derived Factor 1 Scope and Market Size Str…
- ヒトパピローマウイルス（HPV）治療薬の世界市場（～2026年） Market Analysis and Insights: Global Human Papillomaviru Therapeutics Market The global Human Papillomaviru Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Human Papillomaviru Therapeutics Scope and Market…
- ヒトマイクロバイオーム治療薬の世界市場（～2026年） Human microbiome has co-evolved with humans for centuries, which includes bacteria, viruses, fungi, Achaeans etc. The human microbiome is now one of the fastest growing areas of biology, and is considered as a newly discovered organ with the potential to have a tremendous impact on human health. Mic…
- 組換えヒトアルブミンの世界市場（～2026年） Recombinant human albumin (rHA) is a highly purified animal-, virus-, and prion-free product developed as an alternative to human serum albumin (HSA), to which it is structurally equivalent. Market Analysis and Insights: Global Recombinant Human Albumin Market The global Recombinant Human Albumin ma…